<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age>62</patient-age><report-id>PHHO2011US07887</report-id><gender>male</gender><reactions><reaction>Renal dysfunction</reaction><reaction>Acute tubular necrosis</reaction><reaction>Lack of efficacy</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>CERTICAN </drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>PROGRAF</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>PREDNISONE</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>ZAROXOLYN</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>THYMOGLOBULINE                          /FRA/</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Renal transplant</indication></indications><outcomes><outcome>Required Inpatient Hospitalization</outcome></outcomes><country>United States</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4149695_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125152633</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>2</safetyreportversion>
		<safetyreportid>PHHO2011US07887</safetyreportid>
		<primarysourcecountry>US</primarysourcecountry>
		<occurcountry>US</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2013-01-25</transmissiondate>
		<reporttype>2</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2011-05-04</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2013-01-23</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHO2011US07887</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reportertitle>Dr</reportertitle>
			<reportergivename>Mary</reportergivename>
			<reporterfamilyname>Waybill</reporterfamilyname>
			<reporterstreet>205 S Front Street 
Brady 8. Harrisburg, 
PA 17105</reporterstreet>
			<reportercountry>US</reportercountry>
			<qualification code="1">Physician</qualification>
			<sponsorstudynumb>CRAD001AUS92</sponsorstudynumb>
			<observestudytype>1</observestudytype>
		</primarysource>
		<primarysource>
			<reportergivename>Paula</reportergivename>
			<reporterfamilyname>Kratzer</reporterfamilyname>
			<reporterstreet>205 S Front Street 
Brady 8. Harrisburg, 
PA 17105</reporterstreet>
			<reportercountry>US</reportercountry>
			<qualification code="1">Physician</qualification>
			<observestudytype>1</observestudytype>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>REL</patientinitial>
			<patientinvestigationnumb>15</patientinvestigationnumb>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19480605</patientbirthdate>
			<patientweight>137.9</patientweight>
			<patientheight>184</patientheight>
			<patientsex code="1">Male</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Kidney transplant rejection</patientepisodename>
				<patientmedicalstartdateformat>102</patientmedicalstartdateformat>
				<patientmedicalstartdate>20110502</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Drug dose omission</patientepisodename>
				<patientmedicalcomment>By patient</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Oedema peripheral</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Haemodialysis</patientepisodename>
				<patientmedicalstartdateformat>102</patientmedicalstartdateformat>
				<patientmedicalstartdate>20110503</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Renal transplant</patientepisodename>
				<patientmedicalstartdateformat>102</patientmedicalstartdateformat>
				<patientmedicalstartdate>20110412</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Cardiac failure congestive</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Diabetes mellitus</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Nephropathy</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Hypertension</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Renal dysfunction</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Kidney dysfunction</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Renal impairment</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20110502</reactionstartdate>
				<reactionfirsttime>20</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Acute tubular necrosis</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Acute tubular necrosis</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Renal tubular necrosis</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20110502</reactionstartdate>
				<reactionenddateformat>102</reactionenddateformat>
				<reactionenddate>20120519</reactionenddate>
				<reactionduration>384</reactionduration>
				<reactiondurationunit>804</reactiondurationunit>
				<reactionfirsttime>20</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome code="4">recovered/resolved with sequelae</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Lack of efficacy</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Lack of drug effect</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Drug ineffective</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20110502</reactionstartdate>
				<reactionfirsttime>20</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110505</testdate>
				<testname>Biopsy</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110425</testdate>
				<testname>Blood creatinine</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110428</testdate>
				<testname>Blood creatinine</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110502</testdate>
				<testname>Blood creatinine</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110503</testdate>
				<testname>Blood creatinine</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110502</testdate>
				<testname>Blood culture</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110428</testdate>
				<testname>Blood potassium</testname>
				<testresult>4.4</testresult>
				<testunit>mmol/l</testunit>
				<lowtestrange>3.2</lowtestrange>
				<hightestrange>5.1</hightestrange>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110428</testdate>
				<testname>Blood potassium</testname>
				<testresult>4.4</testresult>
				<testunit>mmol/l</testunit>
				<lowtestrange>3.2</lowtestrange>
				<hightestrange>5.1</hightestrange>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110503</testdate>
				<testname>Blood potassium</testname>
				<testresult>6.2</testresult>
				<testunit>mmol/l</testunit>
				<lowtestrange>3.2</lowtestrange>
				<hightestrange>5.1</hightestrange>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110503</testdate>
				<testname>Blood potassium</testname>
				<testresult>6.2</testresult>
				<testunit>mmol/l</testunit>
				<lowtestrange>3.2</lowtestrange>
				<hightestrange>5.1</hightestrange>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110502</testdate>
				<testname>Culture urine</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110502</testdate>
				<testname>Ultrasound kidney</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110428</testdate>
				<testname>Blood urea</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110428</testdate>
				<testname>Haemoglobin</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110428</testdate>
				<testname>Blood albumin</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110428</testdate>
				<testname>Protein total increased</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110428</testdate>
				<testname>Blood sodium</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110428</testdate>
				<testname>Blood chloride</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110428</testdate>
				<testname>Blood calcium</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20110428</testdate>
				<testname>Blood pressure</testname>
				<moreinformation>1</moreinformation>
			</test>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>CERTICAN </medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationnumb>21-560</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>.75</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>12</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="805">Hour</drugintervaldosagedefinition>
				<drugcumulativedosagenumb>29.6299992</drugcumulativedosagenumb>
				<drugcumulativedosageunit code="003">milligrams</drugcumulativedosageunit>
				<drugdosagetext>0.75 mg, Q12H</drugdosagetext>
				<drugdosageform normalized="tablet">Tablet</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Renal transplant</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2011-04-13</drugstartdate>
				<drugstartperiod>20</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2011-05-09</drugenddate>
				<drugtreatmentduration>27</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>EVEROLIMUS</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug ineffective</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug ineffective</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal impairment</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal impairment</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal tubular necrosis</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Renal tubular necrosis</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>PROGRAF</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugstructuredosagenumb>3</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>12</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="805">Hour</drugintervaldosagedefinition>
				<drugcumulativedosagenumb>48</drugcumulativedosagenumb>
				<drugcumulativedosageunit code="003">milligrams</drugcumulativedosageunit>
				<drugdosagetext>3 mg, Q12H</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Renal transplant</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2011-04-25</drugstartdate>
				<drugstartperiod>8</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2011-05-02</drugenddate>
				<drugtreatmentduration>8</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<actiondrug code="3">Dose Increased</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>TACROLIMUS</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>PROGRAF</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugcumulativedosagenumb>48</drugcumulativedosagenumb>
				<drugcumulativedosageunit code="003">milligrams</drugcumulativedosageunit>
				<drugdosagetext>UNK</drugdosagetext>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2011-05-02</drugstartdate>
				<drugstartperiod>8</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<actiondrug code="3">Dose Increased</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>TACROLIMUS</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>PREDNISONE</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugstructuredosagenumb>15</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>15 mg, UNK</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Renal transplant</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2011-04-27</drugstartdate>
				<drugstartperiod>6</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod>1</druglastperiod>
				<druglastperiodunit>804</druglastperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2011-05-02</drugenddate>
				<drugtreatmentduration>6</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>PREDNISONE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>ZAROXOLYN</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>METOLAZONE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>THYMOGLOBULINE                          /FRA/</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Renal transplant</drugindication>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ANTITHYMOCYTE IMMUNOGLOBULIN</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHO2011US07887, is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>report received on 04 May 2011, from clinical study CRAD001AUS92. This 62-year old male subject [centre number 547, subject number 15] was enrolled in a12 month, multi centre, randomized, open label non inferiority study <Semaphore x="1803212" class="Procedure" value="Comparison of Screening Methods" score="1.00" ID="C62743">comparing </Semaphore>the safety and efficacy of concentration <Semaphore x="1854518" class="Disease or Finding" value="Disease Controlled" score="1.00" ID="C82500">controlled </Semaphore><Semaphore x="558929" class="Medicine" value="everolimus" score="0.49" ID="232653">Everolimus </Semaphore>with <Semaphore x="2125081" class="Procedure" value="Low-Dose Treatment" score="1.00" ID="C49341">low dose </Semaphore><Semaphore x="1244668" class="Medicine" value="Tacrolimus" score="0.74" ID="268063">tacrolimus </Semaphore>to <Semaphore x="317973" class="Medicine" value="Cellcept" score="0.49" ID="239619">CellCept </Semaphore>(<Semaphore x="894462" class="Medicine" value="mycophenolate mofetil" score="0.49" ID="279461">mycophenolate mofetil</Semaphore>) with standard dose <Semaphore x="1244668" class="Medicine" value="Tacrolimus" score="0.74" ID="268063">tacrolimus </Semaphore>in de novo <Semaphore x="3228018" class="MedDRA LLT" value="Renal transplant" score="1.00" ID="10038533">renal <Semaphore x="1992543" class="AnatomicStructure" value="Graft" score="1.00" ID="C12981">transplant </Semaphore></Semaphore>recipients.The subject's medical history included <Semaphore x="2840807" class="MedDRA LLT" value="Cardiac failure congestive" score="1.00" ID="10007559"><Semaphore x="2010076" class="Disease or Finding" value="Heart Failure" score="1.00" ID="C50577"><Semaphore x="1808741" class="Disease or Finding" value="Congestive Heart Failure" score="1.00" ID="C3080"><Semaphore x="2010076" class="Disease or Finding" value="Heart Failure" score="1.00" ID="C50577"><Semaphore x="1808741" class="Disease or Finding" value="Congestive Heart Failure" score="1.00" ID="C3080">congestive <Semaphore x="2010076" class="Disease or Finding" value="Heart Failure" score="1.00" ID="C50577">heart <Semaphore x="2459546" class="Disease or Finding" value="Renal Failure" score="1.00" ID="C4376">failure</Semaphore></Semaphore></Semaphore>
         <Semaphore x="2010076" class="Disease or Finding" value="Heart Failure" score="1.00" ID="C50577">
          <Semaphore x="3227032" class="MedDRA LLT" value="Renal failure" score="1.00" ID="10038435">
           </Semaphore></Semaphore>
         <Semaphore x="3227032" class="MedDRA LLT" value="Renal failure" score="1.00" ID="10038435">
          </Semaphore></Semaphore>
       <Semaphore x="2010076" class="Disease or Finding" value="Heart Failure" score="1.00" ID="C50577">
        <Semaphore x="3227032" class="MedDRA LLT" value="Renal failure" score="1.00" ID="10038435">
         <Semaphore x="2459546" class="Disease or Finding" value="Renal Failure" score="1.00" ID="C4376">, </Semaphore></Semaphore></Semaphore>
       <Semaphore x="3227032" class="MedDRA LLT" value="Renal failure" score="1.00" ID="10038435">
        </Semaphore></Semaphore>
      <Semaphore x="3227032" class="MedDRA LLT" value="Renal failure" score="1.00" ID="10038435">
       </Semaphore></Semaphore>
     <Semaphore x="3227032" class="MedDRA LLT" value="Renal failure" score="1.00" ID="10038435">
      </Semaphore></Semaphore>
    <Semaphore x="3227032" class="MedDRA LLT" value="Renal failure" score="1.00" ID="10038435">
     <Semaphore x="2459546" class="Disease or Finding" value="Renal Failure" score="1.00" ID="C4376"><Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985">diabetes mellitus</Semaphore>, <Semaphore x="2088512" class="AnatomicStructure" value="Kidney" score="1.00" ID="C12415">renal </Semaphore></Semaphore>
     <Semaphore x="3138800" class="MedDRA LLT" value="Nephropathy" score="1.00" ID="10029151">
      <Semaphore x="2459496" class="AnatomicStructure" value="Renal Efferent Vessel" score="1.00" ID="C33457">
       <Semaphore x="2459445" class="Disease or Finding" value="Renal Disorder" score="1.00" ID="C3149">
        </Semaphore></Semaphore></Semaphore></Semaphore>
    <Semaphore x="3138800" class="MedDRA LLT" value="Nephropathy" score="1.00" ID="10029151">
     <Semaphore x="2459496" class="AnatomicStructure" value="Renal Efferent Vessel" score="1.00" ID="C33457">
      <Semaphore x="2459445" class="Disease or Finding" value="Renal Disorder" score="1.00" ID="C3149">
       <Semaphore x="2088512" class="AnatomicStructure" value="Kidney" score="1.00" ID="C12415">disease </Semaphore></Semaphore></Semaphore></Semaphore>including <Semaphore x="2294306" class="Disease or Finding" value="Nephrolithiasis" score="1.00" ID="C114667">nephrolithiasis </Semaphore>and <Semaphore x="1607320" class="Disease or Finding" value="Blood Pressure Finding" score="1.00" ID="C54707">hypertension</Semaphore>. The subject underwent <Semaphore x="2088488" class="Procedure" value="Kidney Transplantation" score="1.00" ID="C15265"><Semaphore x="2087096" class="Procedure" value="Kidney Biopsy" score="1.00" ID="C51699">kidney </Semaphore>transplant </Semaphore>on 12 Apr 2011. Concomitant medications included <Semaphore x="1372704" class="Medicine" value="Zaroxolyn" score="0.49" ID="241623">Zaroxolyn </Semaphore>and <Semaphore x="1272670" class="Medicine" value="Thymoglobulin" score="0.74" ID="249269">Thymoglobulin</Semaphore>. The subject started RAD001, at a dose of 0.75mg Q12h, on 13 Apr 2011. He started <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with <Semaphore x="1089682" class="Medicine" value="Prograf" score="0.93" ID="240097">Prograf</Semaphore>, at a dose of 3mg Q12h, on 25 Apr 2011 and started <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with <Semaphore x="1081881" class="Medicine" value="predniSONE" score="0.87" ID="291353">prednisone</Semaphore>, at a dose of 15mg QD, on 27 Apr 2011. On 28 Apr 2011, the subject had <Semaphore x="1607623" class="Procedure" value="Blood Urea Nitrogen Measurement" score="1.00" ID="C61019">blood <Semaphore x="1316129" class="Medicine" value="Urea" score="0.49" ID="194669">urea </Semaphore>nitrogen </Semaphore>30 (unknown units), <Semaphore x="2507267" class="AnatomicStructure" value="Serum" score="1.00" ID="C13325">serum </Semaphore><Semaphore x="1821896" class="Procedure" value="Creatinine Measurement" score="1.00" ID="C64547">creatinine </Semaphore>2.0 (unknown units), <Semaphore x="2014841" class="Procedure" value="Hemoglobin Measurement" score="1.00" ID="C64848">hemoglobin </Semaphore>9.5 (unknown units), <Semaphore x="1469401" class="Procedure" value="Albumin Measurement" score="1.00" ID="C64431">albumin </Semaphore>2.8 (unknown units), <Semaphore x="2507267" class="AnatomicStructure" value="Serum" score="1.00" ID="C13325">serum </Semaphore><Semaphore x="3208968" class="MedDRA LLT" value="Protein total" score="1.00" ID="10050537">total <Semaphore x="2433448" class="Procedure" value="Protein or Enzyme Type Measurement" score="0.68" ID="C64430">protein </Semaphore></Semaphore>6.0 (unknown units), electrolytes including <Semaphore x="2536895" class="Procedure" value="Sodium Measurement" score="1.00" ID="C64809">sodium </Semaphore>148 (unknown units), <Semaphore x="1848940" class="Procedure" value="Dietary Protocol" score="1.00" ID="C93051">potassium </Semaphore>4.4 (unknown units), chlorine 113 (unknown units), <Semaphore x="287292" class="Medicine" value="Calcium" score="0.49" ID="240008">calcium </Semaphore>22.5 (unknown units), <Semaphore x="1607320" class="Disease or Finding" value="Blood Pressure Finding" score="1.00" ID="C54707">blood pressure </Semaphore>152/84 (unknown units). On 29 Apr 2011, the subject missed his morning medications. On 02 May 2011, 20 days after initiation of RAD001, 8 days after initiation of <Semaphore x="1089682" class="Medicine" value="Prograf" score="0.93" ID="240097">Prograf </Semaphore>and 6 days after initiation of <Semaphore x="1081881" class="Medicine" value="predniSONE" score="0.87" ID="291353">prednisone</Semaphore>, a transplanted <Semaphore x="3293856" class="MedDRA LLT" value="Ultrasound kidney abnormal" score="1.00" ID="10045422"><Semaphore x="2087096" class="Procedure" value="Kidney Biopsy" score="1.00" ID="C51699">kidney </Semaphore>ultrasound showed abnormal </Semaphore>resisting of the arcuate <Semaphore x="1545159" class="AnatomicStructure" value="Artery" score="1.00" ID="C12372">arteries</Semaphore>. <Semaphore x="1821896" class="Procedure" value="Creatinine Measurement" score="1.00" ID="C64547">Creatinine </Semaphore>on this date was 6.9. <Semaphore x="2804598" class="MedDRA LLT" value="Blood culture" score="1.00" ID="10005485"><Semaphore x="2819852" class="MedDRA LLT" value="Blood urine" score="1.00" ID="10005863"><Semaphore x="1608509" class="AnatomicStructure" value="Blood" score="1.00" ID="C12434">Blood </Semaphore>and <Semaphore x="2671993" class="AnatomicStructure" value="Urinary System" score="1.00" ID="C12413">urine </Semaphore></Semaphore>
     <Semaphore x="2889932" class="MedDRA LLT" value="Culture urine" score="1.00" ID="10011638">cultures </Semaphore></Semaphore>were performed, the <Semaphore x="1910095" class="Disease or Finding" value="Experimental Result" score="1.00" ID="C76125">results </Semaphore>were pending. On this date <Semaphore x="1089682" class="Medicine" value="Prograf" score="0.93" ID="240097">Prograf </Semaphore>was <Semaphore x="1863405" class="Procedure" value="Dose Increased" score="1.00" ID="C49503">dose increased</Semaphore>. An ultrasound on this date showed abnormal resisting of the arcuate <Semaphore x="1545159" class="AnatomicStructure" value="Artery" score="1.00" ID="C12372">arteries </Semaphore>and was suspicious for rejection. The investigator reported this as renal dysfunction. On an unknown date, the subject had decreased <Semaphore x="2088512" class="AnatomicStructure" value="Kidney" score="1.00" ID="C12415">urinary </Semaphore>output. The subject was hospitalized on an unknown date due to the event and <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with <Semaphore x="1208955" class="Medicine" value="Solu-MEDROL" score="0.74" ID="241635">Solu Medrol </Semaphore>and <Semaphore x="315365" class="Medicine" value="cefepime" score="0.49" ID="241833">Cefepime </Semaphore>was started. On 03 May 2011 <Semaphore x="1821896" class="Procedure" value="Creatinine Measurement" score="1.00" ID="C64547">creatinine </Semaphore>was 8.2 and <Semaphore x="2814900" class="MedDRA LLT" value="Blood potassium normal" score="1.00" ID="10005726"><Semaphore x="1848940" class="Procedure" value="Dietary Protocol" score="1.00" ID="C93051">potassium </Semaphore>was 6.2mmol/l (normal </Semaphore>= 3.3 - 5.1mmol/l). The subject was treated with <Semaphore x="2014361" class="Procedure" value="Hemodialysis" score="1.00" ID="C15248">hemodialysis </Semaphore>and given a dose of <Semaphore x="1272670" class="Medicine" value="Thymoglobulin" score="0.74" ID="249269">Thymoglobulin</Semaphore>. On 05 May 2011, the <Semaphore x="2087096" class="Procedure" value="Kidney Biopsy" score="1.00" ID="C51699">renal biopsy </Semaphore>was performed, which showed <Semaphore x="1426739" class="Disease or Finding" value="Acute Renal Failure with Tubular Necrosis" score="1.00" ID="C34749">acute tubular necrosis</Semaphore>. On 09 May 2011, the study <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drug </Semaphore>was discontinued due to the event (took last dose on 09 May 2011). The subject received immunosuppressants, antimicrobials and <Semaphore x="1861041" class="Procedure" value="Diuretic Measurement" score="1.00" ID="C75384">diuretics </Semaphore>unspecified on an unknown date. The investigator indicated that the events were due to lack of efficacy stating that the subject may not have been immunosuppressed enough especially in light of missed medication dosing. The subject's condition was recovered with sequelae as of 19 May 2012 for the event of <Semaphore x="1426739" class="Disease or Finding" value="Acute Renal Failure with Tubular Necrosis" score="1.00" ID="C34749">acute tubular necrosis</Semaphore>. On the same day, the subject was discharged from the hospital. At the time of reporting, the subject's condition was persisting for the events of renal dysfunction and lack of efficacy. The events were considered serious (<Semaphore x="3012166" class="MedDRA LLT" value="Hospitalisation" score="1.00" ID="10054112">hospitalization</Semaphore>) by the investigator.The investigator suspected a relationship between the events and RAD001, <Semaphore x="1089682" class="Medicine" value="Prograf" score="0.93" ID="240097">Prograf </Semaphore>and <Semaphore x="1081881" class="Medicine" value="predniSONE" score="0.87" ID="291353">prednisone</Semaphore>.Follow up <Semaphore x="1862781" class="Race" value="Dominican" score="1.00" ID="C67117">DR </Semaphore>report received on 22 Aug 2012: The investigator confirmed that, the event renal dysfunction was serious <Semaphore x="2724216" class="MedDRA LLT" value="Adverse event" score="1.00" ID="10060933">adverse event </Semaphore>(previously coded as consequence on the subject's medical history page).Follow up report received on 01 Oct 2012: Updated <Semaphore x="2091429" class="Disease or Finding" value="Laboratory Test Result" score="1.00" ID="C36292">lab </Semaphore>data, <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>medication, <Semaphore x="2308902" class="Procedure" value="New Diagnosis" score="1.00" ID="C54731">new diagnosis </Semaphore>(<Semaphore x="1426739" class="Disease or Finding" value="Acute Renal Failure with Tubular Necrosis" score="1.00" ID="C34749">acute tubular necrosis</Semaphore>) with onset, seriousness, causality and <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome</Semaphore>.Follow up checklist for <Semaphore x="2459546" class="Disease or Finding" value="Renal Failure" score="1.00" ID="C4376"><Semaphore x="2459717" class="Disease or Finding" value="Renal Impairment" score="1.00" ID="C114592">renal impairment </Semaphore>or failure </Semaphore>received on 23 Jan 2013: Updated medical history, laboratory information, <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>medications.</narrativeincludeclinical>
				<sendercomment>Serious adverse drug reaction report, (hospitalisation), assessed as expected according to the Investigator's Brochure. Investigator causality is suspected.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>